Advertisement
Family history may eclipse sun exposure in some cases
Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’
Extent of baseline burden impacts progression-free and overall survival
Further study warranted to better understand the clinical implications of these findings
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Advertisement
Advertisement